Santhera launches DMD therapy in the UK following NICE nod – Pharmaceutical Technology
Santhera’s Agamree is indicated for patients aged four years and older with Duchenne muscular dystrophy (DMD). Credit: JohnnyGreig via Getty Images. Swiss biotech Santhera Pharmaceuticals